SCHEMBL7463269

SCHEMBL7463269

CC(C)(C)OC(=O)N1CCN(c2ccc([N+](=O)[O-])c3ccccc23)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSB P07858 2/20 0.60
AR P10275 1/20 0.60
MAPT P10636 5/20 0.58
LMNA P02545 4/20 0.58
ALDH1A1 P00352 3/20 0.58
MET P08581 1/20 0.48
CHRM2 P08172 1/20 0.46
CHRM4 P08173 1/20 0.46
CHRM1 P11229 1/20 0.46
CHRM3 P20309 1/20 0.46
MAPK1 P28482 1/20 0.46
BACE1 P56817 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GPR119 Q8TDV5 1/20 0.44
MTOR P42345 1/20 0.44
RAB9A P51151 1/20 0.44
SIRT2 Q8IXJ6 1/20 0.44
SMARCA2 P51531 1/20 0.44
SMARCA4 P51532 1/20 0.44
PBRM1 Q86U86 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6761253 0.99 CTSB (0.59) CTSBARMAPTLMNAALDH1A1
SCHEMBL30998112 0.85 MAPT (0.63) MAPTLMNAALDH1A1METMAPK1
SCHEMBL4435451 0.85 MAPT (0.63) MAPTLMNAALDH1A1METMAPK1
SCHEMBL29741481 0.85 MAPT (0.65) CTSBMAPTLMNAALDH1A1CHRM1
SCHEMBL28520810 0.85 MTOR (0.64) CTSBMAPTLMNAALDH1A1MAPK1
SCHEMBL28524484 0.85 MAPT (0.65) CTSBMAPTLMNAALDH1A1CHRM1
SCHEMBL3613661 0.84 CTSB (0.43) CTSBARMAPTLMNAALDH1A1
SCHEMBL3624023 0.84 AR (0.52) CTSBARMAPTLMNAALDH1A1
SCHEMBL3624869 0.82 CTSB (0.69) CTSBARMAPTLMNAALDH1A1
SCHEMBL30965511 0.82 MAPT (0.59) MAPTLMNAALDH1A1METMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118271284-A Estrogen receptor modulators and uses thereof 江苏威凯尔医药科技有限公司 2024-07-02 CN disclosed
CN-101402601-A Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes BIOVITRUM AB PUBL (SE) 2009-04-08 CN disclosed
CN-100457726-C Substituted sulfonamide compounds, process for their preparation and their use as medicaments for the treatment of CNS disorders, obesity and type II diabetes CAMBRIDGE BIOTECHNOLOGY LTD (SE) 2009-02-04 CN disclosed
CN-1800185-A Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes. BIOVITRUM AB (SE) 2006-07-12 CN disclosed
CN-1522245-A Substituted sulfonamide compounds, process for their preparation and their use as medicaments for the treatment of CNS disorders, obesity and type II diabetes �Ȱ�ά����ķ�ɷݹ�˾ 2004-08-18 CN disclosed
EP-0885213-A4 FIBRINOGEN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 1999-04-28 EP disclosed
EP-0885213-A1 FIBRINOGEN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1998-12-23 EP disclosed
WO-1997025323-A1 FIBRINOGEN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-07-17 WO disclosed